Cargando…

To evaluate the impact of a nurse-led JIA education program on parental satisfaction regarding knowledge of JIA and its management

Detalles Bibliográficos
Autores principales:	Jones, J, Munro, J, Williams, T, Augustine, A, Taylor, K, Piper, S, Allen, R, Akikusa, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194419/ http://dx.doi.org/10.1186/1546-0096-9-S1-O24

Ejemplares similares

4.4 Different phenotype of anaemia in systemic juvenile idiopathic arthritis (s-JIA) compared to anaemia in other subtypes of JIA
por: Hinze, CH, et al.
Publicado: (2008)

Histone antibodies as a biomarker of uveitis in JIA
por: Nordal, Ellen B, et al.
Publicado: (2014)

The effects of early aggressive therapy in JIA: results of the TREAT study
por: Wallace, Carol A, et al.
Publicado: (2012)

IL-18 production upon s100 stimulation is reduced in active sJIA patients compared to sJIA patients in remission and healthy controls
por: Haar, Nienke Ter, et al.
Publicado: (2014)

Epidemiology of JIA
por: Lahdenne, Pekka
Publicado: (2014)

Serious infections in JIA patients upon MTX, TFN inhibitors and combinations
por: Horneff, Gerd, et al.
Publicado: (2014)

Safety and efficacy of varicella vaccination in children with JIA treated with biologic therapy
por: Toplak, Natasa, et al.
Publicado: (2014)

Can inflammatory markers predict response to methotrexate in JIA? Results from the CHARM study
por: Moncrieffe, H, et al.
Publicado: (2011)

JIA pathogenesis - genetics
por: Thomson, Wendy
Publicado: (2014)

Response to Jia and Wang
por: Liu, Xu, et al.
Publicado: (2020)

14.4 Oligoarticular Juvenile Idiopathic Arthritis (JIA): can extension be predicted?
por: Hunter, PJ, et al.
Publicado: (2008)

PReS-FINAL-2002: Adverse events during anti-TNF therapy in patients with JIA
por: Tarkiainen, M, et al.
Publicado: (2013)

MEFV mutations in systemic JIA
por: Aktay Ayaz, N, et al.
Publicado: (2008)

Mesenchymal stem cells and JIA
por: Swart, JF, et al.
Publicado: (2011)

eJIAS: Editor's Welcome
por: Wainberg, Mark A
Publicado: (2004)

The swedish paediatric JIA-registry
por: Magnusson, Bo
Publicado: (2014)

Monitoring local inflammation in JIA
por: Roth, Johannes
Publicado: (2014)

Puberty and disease activity in JIA
por: Van Pelt, Philomine, et al.
Publicado: (2014)

Clinical classification of JIA in Albania
por: Vula, Aurel, et al.
Publicado: (2014)

Progressive Pseudorheumatoid Dysplasia or JIA?
por: Wickrematilake, Geetha
Publicado: (2017)

Adverse events of methotrexate treatment in JIA
por: in ‘t Veld, J, et al.
Publicado: (2011)

Recombinant IL1-RA in the early phase of systemic onset JIA: before the onset of arthritis
por: Vastert, SJ, et al.
Publicado: (2011)

Characterising inflammatory markers in two childhood autoimmune diseases (JIA and JDM) pre and post methotrexate
por: Ursu, S, et al.
Publicado: (2011)

2.1 Long-term safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis (JIA)
por: Yokota, S, et al.
Publicado: (2008)

Acute respiratory infections, influenza-like illness and JIA: impact on disease activity and response to the influenza vaccine
por: Carvalho, Luciana M, et al.
Publicado: (2012)

Predictors of response in patients with active systemic JIA (SJIA) receiving canakinumab: an exploratory analysis of pooled 12-week data
por: Ruperto, N, et al.
Publicado: (2014)

How do parents of children with juvenile idiopathic arthritis (JIA) perceive their therapies?
por: Rouster-Stevens, Kelly, et al.
Publicado: (2008)

Psychological Effects and Quality of Life in Parents and Children with Jia-Associated Uveitis
por: Guerriero, Silvana, et al.
Publicado: (2022)

Determing an “autoimmune” phenotype in systemic JIA
por: Fischer, N, et al.
Publicado: (2011)

Evaluation of the JIA treatment with adalimumab in ukraine
por: Ponochevna, Elena, et al.
Publicado: (2014)

Light People: Professor Baohua Jia
por: Guo, Siqiu
Publicado: (2022)

Akinra restores the defective IL-18 NK cell axis in steroid naïve systemic onset JIA patients
por: de Jager, W, et al.
Publicado: (2011)

Effect of ANA positivity on clinical picture of the JIA: should ANA positive JIA be classified as a different group?
por: Polat, Adem, et al.
Publicado: (2011)

PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
por: Lu, P, et al.
Publicado: (2013)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
por: De Benedetti, Fabrizio, et al.
Publicado: (2012)

S100A12 as diagnostic tool in the differential diagnosis of sJIA associated MAS vs. hereditary or acquired HLH
por: Holzinger, D, et al.
Publicado: (2015)

Trajectories of disease courses in the inception cohort of newly diagnosed patients with JIA (ICON-JIA): the potential of serum biomarkers at baseline
por: Ganeva, Margarita, et al.
Publicado: (2021)

The successes and challenges of harmonising juvenile idiopathic arthritis (JIA) datasets to create a large-scale JIA data resource
por: Lawson-Tovey, Saskia, et al.
Publicado: (2023)

Neutrophils: the forgotten cell in JIA disease pathogenesis
por: Jarvis, James N, et al.
Publicado: (2007)

Ocular threat in juvenile idiopathic arthritis (JIA)
por: Marvillet, I, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_tkvmlu0vure0i5hljvgs0fqj4v